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The pathophysiological mechanisms that regulate immune reactions in response to
pharmacological manipulation are the subject of immunopharmacology. Therefore, in-
sights into immunopharmacological patho-mechanisms are relevant to both non-immuno-
logical and immunological phenomena. Pathophysiologically, estrogens are steroid hor-
mones that affect the growth, differentiation and function of female reproductive organs in-
cluding the breast. In addition, several epidemiological, clinical and experimental stud-
ies have suggested that estrogens are strongly involved in breast cancer pathology (1, 2).
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There are substantial experimental, epidemiological and
clinical evidences that show that breast cancer pathology
is influenced by endogenous estrogens. This knowledge
is the foundation upon which endocrine deprivation the-
rapy has been developed as a major modality for the ma-
nagement of breast cancer. Tamoxifen, which functions
as a competitive partial agonist-inhibitor of estrogen at
its receptor, has been widely used for more than three
decades for adjuvant endocrine treatment in breast can-
cer. Currently, other effective drugs for endocrine therapy
include raloxifene, different aromatase inhibitors (particu-
larly third-generation agents) and luteinizing hormone-
-releasing hormone agonists. In recent years, a growing
body of evidence suggests that these drugs can also act
as immune modulators by altering the function of vari-
ous leukocytes and the release of different cytokines.
Moreover, there is evidence that anti-estrogens may
prove to be beneficial in the treatment or prevention of
some autoimmune diseases due to their effects on im-
mune function. However, their immunopharmacological
aspects in the present state of knowledge are not preci-
sely comprehensible. Only a clear pathophysiological un-
derstanding could lead to an efficient strategy for breast
cancer prevention and decrease in the mortality due to
this disease.
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Under the influence of luteinizing hormone-releasing hormone (LH-RH) [or gonado-
tropin-releasing hormone (GnRH)], gonadotropins, viz. luteinizing hormone (LH) and
follicle-stimulating hormone (FSH), are released from the anterior pituitary and regulate
ovarian secretion of estrogen and progesterone. In postmenopausal women, estrogen
biosynthesis occurs principally in peripheral tissue through the conversion of androste-
nedione (androgen), of both adrenal and ovarian origin, to estrogen. The aromatase en-
zyme complex is mainly responsible for this conversion and adipose tissue is the main
site of peripheral estrogen biosynthesis (Fig. 1). Local production in the target tissue it-
self, particularly in the breast, can occur as well (3). The increased rate of conversion of
androgens into estrogens in peripheral adipose tissue (aromatization) may be responsi-
ble for a higher risk of breast cancer in postmenopausal women (4). However, it is possi-
ble that all estrogenic effects in breast cancer are mediated through estrogen binding to
estrogen receptors (ER), which function as transcriptional factors that regulate the ex-
pression of estrogen-responsive genes (5).
Estrogen has been a major target in the treatment of breast cancer since the end of
the 19th century (6). This concept was the foundation upon which endocrine deprivation
therapy has been developed as a major modality for the treatment of breast cancer (7).
Consequently, there have been investigations of the effect of tamoxifen, the prototype of
selective estrogen receptor modulators (SERMs), in patients with metastatic breast can-
cer. Preliminary clinical studies showed anti-tumor activity, leading to its development
as an effective drug in the treatment of breast cancer. Subsequently, other anti-estrogenic
drugs have been developed such as other SERMs as well as LH-RH agonists (GnRH
agonists), aromatase inhibitors and selective estrogen receptor down-regulators/degra-
ders (SERDs) (Table I).
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LH-RH – luteinizing hormone-releasing hormone, FSH – follicle stimulating hormone, LH – luteinizing hormone,
ACTH – adrenocorticotropic hormone
Fig. 1. An overview of estrogen biosynthesis in the body.
In premenopausal patients, a strategy proven to be successful is the use of sustained
release preparations of LH-RH to cause desensitization of the pituitary gland. As a re-
sult, the reduction in gonadotropins causes chemical oophorectomy. Under normal con-
ditions, LH-RH is released from the hypothalamus in a pulsatile manner, resulting in the
release of LH and FSH from the anterior pituitary. Continuous administration of an LH-
-RH agonist (GnRH agonist) over-stimulates the LH-RH receptors in the pituitary, caus-
ing an initial rise in LH and FSH. However, after a few weeks, the LH-RH receptors be-
come desensitized, leading to decreased release of FSH and LH. The ovaries then res-
pond by decreasing the synthesis of estrogen (8). In contrast, aromatase inhibitors act on
aromatase, which is a useful target because it mediates the last step in the series of steps
involved in steroid biosynthesis and is rate-limiting for estrogen synthesis. Steroidal sub-
strate analogues such as formestane and exemestane inactivate aromatase by binding ir-
reversibly to it. Non-steroidal inhibitors such as letrozole and anastrozole are highly po-
tent and reversible inhibitors, with good specificity for aromatase (Table I). Anastrozole,
letrozole and exemestane (third-generation aromatase inhibitors) have shown a signifi-
cant advantage over the traditional aromatase inhibitor aminoglutethimidein in reduc-
ing circulating estrogen levels in postmenopausal women (9).
Tamoxifen has been the standard adjuvant endocrine therapy for both pre- and
postmenopausal women with ER-positive early breast cancer. However, in postmeno-
pausal women, aromatase inhibitors are more effective than tamoxifen therapy and thus
they are presently used as the first line of treatment and tamoxifen as the second line
(10, 11). In addition to SERMs, a new class of drugs called SERDs have emerged, which
interact with and facilitate ER turnover in cells. One drug of this class, fulvestrant, has
been approved as a third line treatment for ER-positive metastatic breast cancer (12). Ne-
vertheless, the currently used therapeutic agents are tamoxifen (or raloxifene), aroma-
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tase inhibitors, and LH-RH agonists. Aromatase inhibitors significantly lower the serum
estradiol concentration in postmenopausal patients, having no detectable effects on adre-
nocortical steroid formation. In contrast, LH-RH agonists suppress ovarian function, in-
ducing a menopause-like condition in premenopausal women (13).
TAMOXIFEN: RELEVANT PHARMACOLOGY
Tamoxifen and raloxifene are so far the only two drugs approved for the chemopre-
vention of breast cancer (14). Tamoxifen is a derivative of triphenylethylene and is a non-
-steroidal anti-estrogen. It functions as a competitive partial agonist-inhibitor of estro-
gen and binds to the ER of estrogen-sensitive normal tissue and estrogen-dependent tu-
mors. Although tamoxifen acts mainly via ER, it also displays anti-tumor activity in ER-
-negative breast cancer, suggesting other targets. In fact, tamoxifen has effects on several
transduction pathways and diverse ion channels (15). Tamoxifen usually has a good to-
lerability profile and unlike many other endocrine agents, it is efficacious in both pre-
and postmenopausal women. The risk-benefit ratio in regard to the different physiologi-
cal systems may vary between pre- and postmenopausal women. However, it is the com-
bination of efficacy and tolerability that allows tamoxifen to maintain its position as the
hormonal treatment of choice for a considerable number of patients with ER-positive breast
cancer. Tamoxifen is extensively metabolized: hydroxylated metabolites 4-hydroxytamo-
xifen and endoxifen (N-desmethyl-4-hydroxytamoxifen) have a higher affinity for the ER
and are much more potent than the parent drug (16, 17). Unfortunately, despite the clear
advantage of tamoxifen treatment, not all ER-positive patients respond to it and the ini-
tially efficient therapy eventually fails. Tumors may become resistant through different
resistance mechanisms, which include alterations in ER structure and function, altera-
tions in post-receptor interactions, changes in paracrine interactions, alterations in drug
pharmacokinetics and changes in immunity (18–20).
IMMUNE MODULATIONS BY SERMs
Tamoxifen
Effects in breast cancer patients. – It is now clear that tamoxifen treatment modulates
immune responses and it has been shown that tamoxifen effects have a close relation-
ship with the host natural killer (NK) cell function. In an earlier study, lymphocytes from
tamoxifen-treated patients with breast cancer exhibited a significantly lower activity of
NK cells against human myeloid leukemia K562 cells that are killed easily by NK cells in
normal situations. In contrast, the proliferative response of lymphocytes to concanavalin
A was significantly higher (21). Furthermore, Robinson et al. observed significantly redu-
ced NK cell activity in patients with bilateral primary breast cancer treated with tamo-
xifen compared to the pretreatment stage (22). They also noticed that those patients
showed a decrease in CD4+ T cells and proliferative responses, in an autologous mixed
lymphocyte reaction, compared to normal controls. However, among postmenopausal
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breast cancer patients under tamoxifen therapy, Mallmann and Krebs observed an in-
crease in NK cells and a higher number of cases with a positive value in the leukocyte
migration inhibition test in comparison with the control group (23). In combination treat-
ment, tamoxifen was reported to be helpful in preventing a decrease of lymphocytes and
lymphocyte subset counts during radiotherapy and cytotoxic chemotherapy (24, 25). Lu-
kac et al. documented an elevated number of leukocytes including CD4+ and CD8+ lym-
phocytes in breast cancer patients treated with tamoxifen during the post-radiotherapy
period compared to control post-radiotherapy patients. However, granulocyte ingestion
was decreased in the tamoxifen group, possibly indicating an inhibitory effect of the
drug on phagocytic functions (24).
Effects in human and mouse cell lines. – In a study conducted by Baral et al. using hu-
man ovarian and lung carcinoma cases, when cytotoxic T lymphocytes (CTL) were given
in conjunction with anti-estrogens, the lysis of autologous cancer cells was significantly
increased with both tamoxifen and toremifene (26). This phenomenon was further am-
plified by additional treatment with interferon-alpha (IFNa). It was shown through a se-
ries of experiments that tamoxifen potentially influenced the lymphocyte population and
enhanced the immune cell-mediated target-cell destruction by using ascites fluid of ova-
rian carcinoma patients, human lung cancer tissue and the P815 murine mastocytoma.
CTL-mediated, NK cell-mediated and lymphokine-activated killer (LAK) cell-mediated
target-cell lyses were amplified by tamoxifen (26, 27). Correspondingly, using the P815
mastocytoma of DBA/2 mice, it was found that the anti-estrogenic drugs tamoxifen and
toremifene increased the efficiency of immunotherapy by killer cells (28).
EFFECTS OF OTHER SERMs ON IMMUNITY
Raloxifene
In a study on healthy postmenopausal women, raloxifene treatment caused a signifi-
cant decrease in serum interleukin-4 (IL-4) concentrations of patients compared to the
placebo-control group (29).
Similar to tamoxifen, treatment with raloxifene exhibited suppression of estrogen-me-
diated effects on survival, maturation, and activation of autoreactive B cells in NZB/W
F1 mice (30). In addition, similarly to the effect of tamoxifen on dendritic cells, raloxi-
fene reduced the immunostimulatory capacity of murine dendritic cells and inhibited
their differentiation, though the drug-exposed dendritic cells displayed enhanced ability
to internalize antigens (31). Furthermore, in experimental animals, raloxifene corrected
thymic hypertrophy induced by ovariectomy; however, it decreased bone marrow T cell
levels (32). In contrast, a report demonstrated that raloxifene did not modulate the thy-
mic CD4+/CD8+ phenotypes, T cell responsiveness and inflammation in comparison with
estrogen-mediated alterations in mice (33).
145
A. Ray and M. Ficek: Immunomodulatory effects of anti-estrogenic drugs, Acta Pharm. 62 (2012) 141–155.
Toremifene
Some researchers have found that in the blood, lymph nodes and tumors of breast
cancer patients, the concentrations of toremifene and its active N-desmethyl metabolites
reach a peak about 2 weeks after administration; the peak levels were higher than that of
tamoxifen or N-desmethyltamoxifen. Furthermore, the concentrations of toremifene and
N-desmethyl metabolites of toremifene were higher in tumors and lymph nodes than in
blood (34).
Similarly to tamoxifen, toremifene also augmented the immune oncolysis induced
by various killer cells against human ovarian carcinoma cells and the human erythro-
leukemia cell line, K562 (35). It was noticed that in human peripheral blood T cells, both
toremifene and tamoxifen inhibited mitogen-induced proliferation and up-regulated tu-
mor necrosis factor (TNF) receptor family molecules (36). Conversely, tamoxifen was shown
to be stimulatory for TNFa production in cultures of normal human peripheral mono-
nuclear blood cells, but this feature was absent in the case of toremifene (37). Neverthe-
less, it was documented that toremifene exerts multiple and varied effects on the gene
expression of human peripheral mononuclear cells (38). In a study conducted by Järvi-
nen et al., using human cells in vitro, both tamoxifen and toremifene enhanced the T cell-
-dependent antibody production from B cells (39). In addition, they found that these
drugs stimulated overall cytokine production in a B cell line (Ball). Interestingly, tamo-
xifen stimulated IL-1b, IL-6 and IFNg production in a T cell line (Molt-4), whereas to-
remifene inhibited it. In their study, these two anti-estrogenic drugs showed no signifi-
cant effects on cytokine production in myeloid cells (39).
Ormeloxifene
This non-steroidal SERM possesses contraceptive and anti-osteoclastogenic effects.
Furthermore, the drug has been shown to have anti-cancer activities (40). Thomas et al.
(41) demonstrated that ormeloxifene significantly increased the levels of serum immu-
noglobulins in mice. They concluded that ormeloxifene increased humoral immunity,
but had an insignificant effect on cell mediated immunity.
IMMUNE MODULATIONS OF AROMATASE INHIBITORS
It was demonstrated in studies using malignant human breast tissue that aromatase
activity in adipose tissue may have a close association with the cells of the immune sys-
tem, particularly macrophages and the related cytokines (42, 43). Furthermore, the asso-
ciation between elevated aromatase levels and subclinical inflammation was more pro-
minent in the breast tissue of most overweight and obese women (43).
First-generation aromatase inhibitor (aminoglutethimide)
Berry et al. (44) described an increase in NK cell activity in postmenopausal breast
cancer patients on a low dose of aminoglutethimide, a first-generation aromatase in-
hibitor.
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An earlier report, using mouse tissue, demonstrated that aminoglutethimide enhan-
ced delayed hypersensitivity and altered T lymphocyte distribution (45). It was also no-
ticed that following daily administration of aminoglutethimide to female mice, signifi-
cant dropping in white cell counts occurred after 3 weeks (46). However, another study
documented greater proliferation of bovine T lymphocytes in cultures containing ami-
noglutethimide (47).
Second-generation aromatase inhibitors
Interestingly, tumor cells treated with formestane exhibited increased sensitivity to
monocyte-mediated, antibody-dependent cellular cytotoxicity in metastatic breast can-
cer patients. Thus, a hormone-based treatment might collaborate with antigen-specific
tumor immunity to create improved mechanisms for tumor control (48).
Formestane treated mice displayed an increased IL-2 and IFNg release and a decrea-
sed IL-10 release (49). On the other hand, fadrozole was associated with improvement of
the cellular immune response and enhancement of IL-6 levels in male mice (50).
Third-generation aromatase inhibitors
Third-generation aromatase inhibitors include exemestane, anastrozole, letrozole and
vorozole, the latter three being non-steroidal inhibitors. In a study on postmenopausal
patients with breast cancer, Watanabe et al. (51) observed that exemestane administra-
tion could cause a decrease in lymphocyte counts. Alternatively, treatment with anastro-
zole was demonstrated to be associated with an increased expression of genes relating to
inflammatory processes in ER+ breast tumors. Furthermore, there was enhanced induc-
tion of T cell anergy (unresponsiveness) in non-responders and induction of immune re-
sponse in responders (52). In a comparative analysis of tamoxifen and anastrazole adju-
vant treatments, total white blood cells of postmenopausal breast cancer patients were
increased after one year of treatment with both anastrazole and tamoxifen; however, un-
like tamoxifen, anastrazole did not change the lymphocyte count (53). Conversely, there
was a reduction in regulatory T cells (T-reg cells) in letrozole treated elderly breast can-
cer patients and a greater T-reg reduction in responding patients, suggesting that the aro-
matase inhibitor letrozole may have an indirect anti-tumor action via its effects on im-
mune mechanisms (54). Also, immunotherapy (with thymosin a1) reduced aromatase
inhibitor (anastrozole, letrozole, or exemestane) related joint symptoms in postmenopau-
sal breast cancer survivors, indicating involvement of immune phenomena with aroma-
tase inhibitors (55).
Wang et al. (56) found that anastrozole suppressed the differentiation of naive T cells
to T-reg cells, and it blocked the balance of IgG2a/IgG1 in peripheral blood of rats. In
addition, anastrozole increased the levels of pro-inflammatory cytokines, IFNg and IL-12,
and decreased IL-4 and IL-10 levels.
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ANTI-ESTROGENIC DRUGS: CONNECTIONS WITH AUTOIMMUNE DISORDERS
Due to the pleiotrophic nature of tamoxifen, its role in a variety of seemingly unre-
lated disorders, including multiple sclerosis, Parkinson’s disease, Alzheimer’s disease,
systemic lupus erythematosus (SLE) and urological cancers, has been investigated in
many studies (57).
Both anti-estrogens tamoxifen and toremifene were demonstrated to inhibit the ma-
turation of human dendritic cells, a property that could be beneficial in the treatment
and prevention of autoimmune diseases like rheumatoid arthritis (58, 59). Interestingly,
Behjati and Frank (60) suggested a useful role of tamoxifen in the treatment of immu-
ne-mediated disorders, particularly of those arising from aberrant T helper 1 (Th1) cell
activity, including allograft rejection and Th1-mediated autoimmune conditions like
multiple sclerosis, owing to the capability of this drug to induce a shift from cellular (T
helper 1) to humoral (T helper 2) immunity. In this connection, it may be worth mention-
ing that by using mice, Bebo et al. (61) reported a suppressive role of SERMs like tamo-
xifen and raloxifene on myelin antigen specific T cell proliferation in experimental auto-
immune encephalomyelitis.
Sereda and Werth observed an improvement in patients with dermatomyositis-as-
sociated skin eruptions while taking anti-estrogen medication (both tamoxifen and the
aromatase inhibitor anastrozole) (62). Dermatomyositis is an autoimmune disease that
occurs more often in women and causes inflammation of the skin and muscles. In a re-
cent study, Babina et al. (63) found that tamoxifen treatment interfered with all aspects of
the allergic immune response, leading to a reduction of allergen-specific immunoglobu-
lin levels (IgE, IgG1 and IgG2a) and a skewing effect in the T cell compartment with the
inhibition of IL-4 in mice sensitized with ovalbumin-alum by the intra-peritoneal route.
Along with the systemic effects, there was a reduction in local pathologies like dimin-
ished epidermal thickness and decreased CD4+ and CD8+ cell infiltrates.
In recent years, a number of studies have tried to evaluate the beneficial immuno-
logical effects of anti-estrogenic drugs, notably tamoxifen, in SLE. Female subjects have
a higher incidence of certain autoimmune diseases such as SLE and several studies have
reported that estrogens accelerate the course of spontaneous SLE-like disease in NZB/W
F1 and MRL-lpr/lpr mice. It was demonstrated that tamoxifen treatment could favor-
ably influence T cells and modulate the immune function in MRL–lpr/lpr female mice
(64). Similarly, in NZB/W F1 female mice, tamoxifen treatment showed fewer pathologi-
cal features compared to controls by influencing the B cell count, expression of cytokine
receptors and thereby overall immune function (65). Furthermore, in this mouse strain,
autoantibody production directed against either nuclear extracts or DNA was signifi-
cantly reduced by tamoxifen treatment (66). Interestingly, it was found in mice that ta-
moxifen prevented the activation of autoreactive B cells (67). These cells are deleted in
normal conditions; however, their activation can cause an elevation of serum anti-DNA
antibody titers.
Research concerning the immunomodulatory effects of LH-RH agonists and SERDs
is limited and entirely non-existent for some specific anti-estrogenic drugs. Neverthe-
less, available current research concerning the effects of LH-RH agonists and SERDs on
immune parameters has been tabulated in Table II (68–77).
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CONCLUSIONS
The pathology of breast cancer has been shown to be associated with alterations of
different components of body’s immune machinery (78–81). It has been recently propo-
sed that inflammation, in part due to tumor-associated macrophages and proinflamma-
tory cytokines, may promote more aggressive ER-positive tumors and the suggested treat-
ment includes targeting inflammation combined with anti-estrogenic drugs (82). Inter-
estingly, various anti-estrogenic drugs have also been demonstrated to affect the immune
system. The immunomodulatory effects described thus far include alterations in the fun-
ction of lymphocytes, macrophages, monocytes and dendritic cells as well as effects on
cytokines. Additionally, anti-estrogenic drugs have exhibited some immune modulations
related to autoimmune disorders, possibly leading to other uses.
Apart from the hormonal property, many of these drugs may have other mechanisms
of action through which they could modulate immune pathways and exert additional
anti-tumor effects. Although adjuvant hormonal therapy substantially reduces the mor-
bidity and mortality in both pre- and postmenopausal women with ER-positive early
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Table II. Effects of selective estrogen down-regulators and luteinizing hormone releasing hormone agonists
on various immune parameters.
Anti-estrogenic drug Salient findings of the study Reference no.
Fulvestrant (SERD) Fulvestrant depressed IgM in BALB/c mice. 68
Fulvestrant




In ovariectomized rats, fulvestrant inhibited the




Significantly lower median values for the T cell
activation markers CD154 and calcineurin in







Leuprolide increased the number of lymphoid
and myeloid progenitor cells in the bone mar-
row and developing thymocytes in the thymus.
73
Goserelin (LH-RH agonist)
Goserelin treatment normalized cytokine pro-
duction in women with endometriosis.
74
Buserelin (LH-RH agonist)
CD4+ T cell and CD25+ T cell subpopulations
were significantly down-regulated when
buserelin was used for approximately 2 weeks.
75
Buserelin Buserelin treatment increased NK cell activity. 76
Triptorelin (LH-RH agonist)
In this drug treatment, an increase in NK cell
activity was observed among patients with
endometriosis who responded well to it.
77
breast cancer, relapses occur frequently due to the development of drug resistance. Over
the last several years we have observed considerable development in our understanding
of the mechanisms of resistance to anti-estrogenic drugs. Resistance mechanisms may
include phenomena such as activation of growth factor pathways like HER2/ neu sig-
naling (83), enhanced concentrations of some hormone-like cytokines secreted from adi-
pose tissue in obesity – particularly leptin (84), and mutations in the tumor suppressor
gene p53 (85). Although some possible resistance mechanisms have been proposed, de-
tails of these mechanisms are unknown and there are probably some other factors. Alter-
ations in host immunity might be an important factor in the development of resistance
to anti-estrogenic agents in breast cancer patients. Therefore, gaining knowledge of the
effects of anti-estrogenic drugs on immune function may bring us closer to elucidating
some drug resistance pathways and possibly developing drugs with a higher long-term
success rate. Nevertheless, the intricate pharmacology of anti-estrogenic agents is being
slowly comprehended and this has resulted in new drug discoveries. In the near future,
an increasing number of various biological molecules associated with estrogen will be
used as targets for new treatment modalities.
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S A @ E T A K
Imunomodulatorni u~inak antiestrogenih lijekova
AMITABHA RAY i MONICA FICEK
Postoje zna~ajni eksperimentalni, epidemiolo{ki i klini~ki dokazi da na patologiju
karcinoma dojke utje~u endogeni hormoni. Zbog toga je sni`avanje razine hormona naj-
va`niji na~in terapije ove bolesti. Ve} vi{e od tri dekade koristi se tamoksifen, kompeti-
tivni parcijalni agonist-inhibitor receptora za estrogene. U suvremenoj terapiji koriste se
jo{ raloksifen, razli~iti inhibitori aromataze (posebno tre}a generacija inhibitora) i ago-
nisti hormona za osloba|anje luteiniziraju}eg hormona. U posljednje vrijeme sve vi{e
~injenica ukazuje na to da ti lijekovi imaju i imunomodulatorni u~inak, tj. utje~u na funk-
ciju leukocita i osloba|anje razli~itih citokina. [tovi{e, postoje dokazi da antiestrogeni
lijekovi imaju povoljni u~inak na neke autoimune bolesti. Me|utim, njihov imunofarma-
kolo{ki u~inak nije do kraja obja{njen. Samo potpuno razumijevanje patofiziolo{kih pro-
cesa mo`e uroditi u~inkovitom strategijom za prevenciju i terapiju te smanjenje mortali-
teta od karcinoma dojke.
Klju~ne rije~i: karcinom dojke, SERMs, tamoksifen, inhibitori aromataze, imunofarmakologija
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